Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yating Gao

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
BMC Urology|November 1, 2022
The targets of aspirin in bladder cancer: bioinformatics analysisXiao Li, Yanghao Tai, Shuying Liu, et al.
Frontiers in Pharmacology|November 1, 2021
An <i>In-Silico</i>, <i>In-Vitro</i> and <i>In-Vivo</i> Combined Approach to Identify NMNATs as Potential Protein Targets of ProEGCG for Treatment of EndometriosisSze Wan Hung, Bo Liang, Yating Gao, et al.
Acta Pharmaceutica Sinica. B|September 30, 2022
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug <i>Potentilla discolor</i> BungeLongshan Ji, Qian Li, Yong He, et al.
Journal of Virus Eradication|October 27, 2025
Serum osteopontin levels predict short-term outcomes in patients with hepatitis B-related acute-on-chronic liver failureYu Liu, Miao Fang, Hongying Guo, et al.
British Journal of Cancer|April 6, 2026
Suppression of LRRC41-mediated oncogenicity in hepatocellular carcinoma via USP7-targeted small molecule inhibitorsYue Huang, Yiling Xi, Huizong Nie, et al.
Journal of Ethnopharmacology|April 15, 2024
Ba-Qi-Rougan formula alleviates hepatic fibrosis by suppressing hepatic stellate cell activation via the MSMP/CCR2/PI3K pathwayYan Xue, Wanchun Zhu, Fengjie Qiao, et al.
Frontiers in Immunology|August 9, 2021
Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of EndometriosisYing He, Sze Wan Hung, Bo Liang, et al.
Frontiers in Immunology|December 10, 2025
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosisYing He, Sze Wan Hung, Bo Liang, et al.
Heliyon|November 30, 2023
Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinomaRongjie Zhang, Qian Li, Xiaoxiao Yu, et al.
Frontiers in Pharmacology|January 30, 2023
Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implicationsYu Liu, Wei Yuan, Miao Fang, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
BMC Urology|November 1, 2022
The targets of aspirin in bladder cancer: bioinformatics analysisXiao Li, Yanghao Tai, Shuying Liu, et al.
Frontiers in Pharmacology|November 1, 2021
An <i>In-Silico</i>, <i>In-Vitro</i> and <i>In-Vivo</i> Combined Approach to Identify NMNATs as Potential Protein Targets of ProEGCG for Treatment of EndometriosisSze Wan Hung, Bo Liang, Yating Gao, et al.
Acta Pharmaceutica Sinica. B|September 30, 2022
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug <i>Potentilla discolor</i> BungeLongshan Ji, Qian Li, Yong He, et al.
Journal of Virus Eradication|October 27, 2025
Serum osteopontin levels predict short-term outcomes in patients with hepatitis B-related acute-on-chronic liver failureYu Liu, Miao Fang, Hongying Guo, et al.
British Journal of Cancer|April 6, 2026
Suppression of LRRC41-mediated oncogenicity in hepatocellular carcinoma via USP7-targeted small molecule inhibitorsYue Huang, Yiling Xi, Huizong Nie, et al.
Journal of Ethnopharmacology|April 15, 2024
Ba-Qi-Rougan formula alleviates hepatic fibrosis by suppressing hepatic stellate cell activation via the MSMP/CCR2/PI3K pathwayYan Xue, Wanchun Zhu, Fengjie Qiao, et al.
Frontiers in Immunology|August 9, 2021
Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of EndometriosisYing He, Sze Wan Hung, Bo Liang, et al.
Frontiers in Immunology|December 10, 2025
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosisYing He, Sze Wan Hung, Bo Liang, et al.
Heliyon|November 30, 2023
Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinomaRongjie Zhang, Qian Li, Xiaoxiao Yu, et al.
Frontiers in Pharmacology|January 30, 2023
Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implicationsYu Liu, Wei Yuan, Miao Fang, et al.
Pageof 10